These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 23703296)
1. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience. Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296 [No Abstract] [Full Text] [Related]
2. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177 [TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321 [TBL] [Abstract][Full Text] [Related]
4. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248 [TBL] [Abstract][Full Text] [Related]
5. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas]. Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Frenay M; Giroux B; Khoury S; Derlon JM; Namer M Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116 [TBL] [Abstract][Full Text] [Related]
7. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276 [TBL] [Abstract][Full Text] [Related]
9. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471 [TBL] [Abstract][Full Text] [Related]
10. Cystemustine in recurrent high grade glioma. Durando X; Thivat E; Roché H; Bay JO; Lemaire JJ; Verrelle P; Chazal J; Curé H; Chollet P J Neurooncol; 2006 Aug; 79(1):33-7. PubMed ID: 16575534 [TBL] [Abstract][Full Text] [Related]
11. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692 [No Abstract] [Full Text] [Related]
12. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366 [TBL] [Abstract][Full Text] [Related]
13. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Addeo R; De Santi MS; Del Prete S; Caraglia M Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315 [No Abstract] [Full Text] [Related]
14. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Rajan B; Ross G; Lim CC; Ashley S; Goode D; Traish D; Brada M Eur J Cancer; 1994; 30A(12):1809-15. PubMed ID: 7880611 [TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893 [TBL] [Abstract][Full Text] [Related]